Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
189 hedge funds and large institutions have $459M invested in Catalyst Pharmaceutical in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 61 increasing their positions, 72 reducing their positions, and 18 closing their positions.
407% more call options, than puts
Call options by funds: $715K | Put options by funds: $141K
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
4.5% more ownership
Funds ownership: 68.95% → 73.45% (+4.5%)
1% more funds holding
Funds holding: 187 → 189 (+2)
15% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 72
21% less capital invested
Capital invested by funds: $583M → $459M (-$125M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$13.4M |
| 2 |
Millennium Management
New York
|
+$11.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.01M |
| 4 |
Goldman Sachs
New York
|
+$5.92M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$5.51M |
Top Sellers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.81M |
| 2 |
Two Sigma Investments
New York
|
-$4.49M |
| 3 |
BlackRock
New York
|
-$3.6M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$2.5M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.17M |
CPRX Hedge Fund Activity: Q2 2022 in Review
189 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2022, worth a combined $459M — down 21% from $583M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CPRX positions and 18 closed out — a net gain of 6 holders — while 61 added to existing stakes and 72 trimmed.
The largest buyer was Armistice Capital, adding an estimated $13.4M. The largest seller was Federated Hermes, cutting an estimated $4.81M.
- 189 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2022, up from 187 in Q1 2022.
- Funds reported $459M of Catalyst Pharmaceutical stock for Q2 2022, down 21% quarter-over-quarter.
- 24 funds opened new Catalyst Pharmaceutical positions in Q2 2022 and 18 closed out, a net change of +6 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2022 was Armistice Capital, an estimated $13.4M added.
- The largest Catalyst Pharmaceutical seller in Q2 2022 was Federated Hermes, an estimated $4.81M sold.
Based on aggregated 13F filings for Q2 2022.